Alcanza Clinical Research today announced the acquisition of CNS Healthcare, an established independent clinical research network with a three-decade legacy of advancing medical science and patient care. Founded in 1996, CNS Healthcare has completed thousands of clinical trials across key therapeutic areas, including neuroscience and behavioral health. With five locations across Memphis, TN; Jacksonville and Orlando, FL; and a mobile clinical trial vehicle, CNS Healthcare has been a preferred research network for both community participants and global sponsors, recognized for high-quality clinical data and a patient-centric environment.
CNS Healthcare has built a strong reputation for high-quality clinical research, supported by an experienced team of Principal Investigators and many other research professionals. Under the leadership of CEO Dan Kearney, the organization has expanded its capabilities and industry partnerships with a 30-year track record of consistent site performance and trial delivery.
“We are truly excited to join the Alcanza team. Their commitment to inclusiveness in all that they do ties into how we, at CNS Healthcare, have operated for over 30 years. The team at Alcanza has been wonderful to work with and I look forward to seeing the value our combined capabilities will deliver,” said Dan Kearney, CEO of CNS Healthcare.
“Working alongside high-performing clinical research organizations continues to be a key focus for Alcanza. We are pleased to welcome CNS Healthcare and its outstanding team to our growing site network,” said Carlos Orantes, CEO of Alcanza Clinical Research.
The addition of CNS Healthcare further strengthens Alcanza's clinical trial site network of high-performing research sites and expands its multispecialty therapeutic capabilities. With a shared commitment to quality study execution and inclusive patient engagement, the integration of Alcanza and CNS Healthcare enhances the organization's capacity to deliver on its “Clinical Research for All™” mission and significantly broadens its site access throughout diverse communities.
For business and technology leaders, this acquisition signals the growing importance of decentralized and patient-centric clinical trials, particularly in neuroscience and behavioral health—areas with high unmet medical need. By integrating CNS Healthcare’s mobile clinical trial vehicle and established community presence, Alcanza can accelerate enrollment and improve diversity in trials, addressing a critical bottleneck in drug development. The expanded network now includes over 30 locations of dedicated research units and additional integrated specialty clinic sites strategically located throughout the continental US and Puerto Rico, supporting studies across all trial phases and major therapeutic areas.
This move also reflects a broader industry trend toward consolidation in clinical research, as organizations seek to build scale and therapeutic depth to compete for complex, high-value trials. For sponsors and CROs, a larger, more capable site network can reduce timelines and improve data quality, ultimately bringing new treatments to market faster.
